[wpml_language_selector_widget]

Reading and Resources

Resources for Providers and Patients

Articles and Further Reading

  1. Brufsky A, Maculaitis MC, Kopenhafer L, et al. Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices. Future Oncol. 2024;20(29):2165-2177.
  2. Cardoso F, Bese N, Distelhorst SR, et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast. 2013;22(5):593-605.
  3. Das A, Lavanya KJ, Nandini, et al. Effectiveness of selective estrogen receptor modulators in breast cancer therapy: an update. Curr Med Chem. 2023;30:3287-3314.
  4. Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106.
  5. Jerzak KJ, Bouganim N, Brezden-Masley C, et al. HR+/HER2- advanced breast cancer treatment in the first-line setting: expert review. Curr Oncol. 2023;30(6):5425-5447.
  6. Kida K, Olver I, Yennu S, et al. Optimal supportive care for patients with metastatic breast cancer according to their disease progression phase. JCO Oncol Pract. 2021;17(4):177-183.
  7. Loibl S, Furlanetto J. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast. 2022;62:S70-S79.
  8. Ray SK, Mukherjee S. Breast cancer stem cells as novel biomarkers. Clin Chim Acta. 2024;557:117855.
  9. Rugo HS. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician’s perspective. Clin Adv Hematol Oncol. 2023;21:623-632.
  10. Smolarz B, Nowak AZ, Romanowicz H. Breast cancer: epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022;14(10):2569.
  11. Tan PH, Ellis I, Allison K, et al, WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181-185.
  12. Wang X, Zhao S, Xin Q, et al. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Ther. 2024;31:1283-1291.
  13. Wysocka J. New WHO classification of breast tumours. J Oncol. 2020;70:250-252. https://onlinelibrary.wiley.com/doi/full/10.1111/his.14091

Understanding HR+/HER2- Breast Cancer

Epidemiology and Pathophysiology

Assessment and Biomarkers

Treatment and Management

Patient Support Strategies

Reading and Resources

CME Highlights

This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Lilly.
Copyright © 2025 | Med Learning Group | All Rights Reserved | Website by Divigner

Pin It on Pinterest

Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers